Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

AgePhagy

Financiado

Cerrado

An integrated high throughput human cell and Drosophila screening platform for t...

An integrated high throughput human cell and Drosophila screening platform for the expedited discovery of anti ageing compounds The steeply increasing ageing population, and accompanying rise of age-related diseases will soon have profound societal and economic effects, making ageing research increasingly important and outcome of this grant impactful. Our... ver más

30/09/2020

UNIVERSITY COLLEGE...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-09-30

ERC-2018-PoC: ERC Proof of Concept Grant

I+D

Cerrada hace 7 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNIVERSITY COLLEGE LONDON

149.87K€ | Lider

GUARDIAN LLODIO UNO

786.40K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2021-126280OB-I00 ACTIVACION DE CYB5R3 Y DE LA BIOSINTESIS DEL NAD+ COMO NUEVA... 169K€ Cerrado

EpiMetAgeing Epitranscriptomics at the crossroads of metabolism and cellu... 161K€ Cerrado

GeroProtect Developing Geroprotectors to Prevent Polymorbidity 3M€ Cerrado

BFU2016-75116-P MAPA GLOBAL DE LOS MECANISMOS MOLECULARES QUE REGULAN EL ENV... 145K€ Cerrado

LifeLongFit Late life-applicable enhancement of longevity and fitness. 2M€ Cerrado

PID2020-115189GB-I00 ENTENDIENDO EL IMPACTO DE LA UTILIZACION DE DOSIS SERIADAS D... 182K€ Cerrado

Duración del proyecto: 18 meses Fecha Inicio: 2019-03-26
Fecha Fin: 2020-09-30

Líder del proyecto

UNIVERSITY COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The steeply increasing ageing population, and accompanying rise of age-related diseases will soon have profound societal and economic effects, making ageing research increasingly important and outcome of this grant impactful. Our most promising way to improve health in the elderly is by replicating decades of genetic finding in model organisms of healthy long-lived mutants to pharmacological approaches. This will enable transition of these findings to clinical trials. In the CancerPhagy project, we showed that genetic upregulation of autophagy, major cellular degradation pathway, increased lifespan, which we aim to mimic by pharmacological treatment. To this end, we developed the CellAge epigenetic clock, which is based on DNA methylation and which is the first clock that accurately detects subtle ageing changes in human primary cells in vitro upon a short anti-ageing drugs treatment, as shown using rapamycin and trametinib. This differentiates our clock from other available epigenetic clocks which are designed to accurately determine human age in years. By connecting the CellAge clock to autophagy drug library we will test the commercial viability of our anti-ageing drug assessment platform. To further validate our CellAge clock as a robust human ageing biomarker, we will combine its outputs with longevity assays in vivo in Drosophila. The final outcome will be an innovative and accelerated discovery platform for sought after anti-ageing/geroprotector drugs, which we will in this first instance test autophagy modifier drugs. Throughout the project we will closely collaborate with our industrial collaborator, GSK and UCL Business, which will assure we maximise the potential of our platform. Our ultimate goal is to uncover novel autophagy modifiers with anti-ageing properties and to launch the CellAge clock as the most advanced platform for expedited discovery of anti-ageing compounds.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores